Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

BOSTON, Nov. 11, 2013 /PRNewswire/ -- InspireMD Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection stents, today announced financial results for the quarter ended September 30, 2013.

Key Highlights of Recent Events

  • MGuard™ outperformed bare metal and drug eluting stents in all-cause mortality in STEMI patients for the 12-month follow-up data from the MASTER Trial
  • Secured $10 million in venture debt financing to support product development and clinical expansion
  • Initiated direct selling activities in Germany
  • Upcoming Near-term Milestones

  • Expanding direct selling organization and activities in other key European countries
  • Accelerating product development and clinical programs to expand the MicroNet therapeutic platform to a drug eluting stent, as well as for carotid and peripheral artery
  • CGuard™ first in man carotid stent trial initiation planned for Q1 2014
  • "The positive mortality data from the MASTER trial 12-month follow-up is being well received by physicians since the results were announced at the TCT conference just two weeks ago.  We believe this data will be an important factor in our efforts to increase adoption rates for the MGuard and for recruitment in the MASTER II trial," stated Alan Milinazzo, President and Chief Executive Officer of InspireMD.  "The acute benefits reported with the MGuard in ST segment resolution, improved TIMI flow and reduced infarct size, gives us the confidence that these improved clinical results are achieved due to the embolic protection benefits of our MicroNet technology."

    "Encouraged by the MASTER trial 12-month data, we believe there is significant potential for our platform technology, MicroNet, to support a broader pipeline of devices in the coronary and vascular setting. We recently put into place a financing strategy that off
    '/>"/>

    SOURCE InspireMD
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. InspireMD Announces First Quarter 2012 Financial Results
    2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
    3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
    4. InspireMD to Present at Harvard Investors Group on June 27 in New York
    5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
    6. InspireMD Reports Results For Period Ending Sept. 30, 2012
    7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
    8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
    9. InspireMD Reports Results for Period Ended Dec. 31, 2012
    10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
    11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
    (Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
    (Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
    Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
    (Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
    (Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
    (Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
    (Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
    (Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
    Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
    ... ALTO, Calif., April 29 Varian Medical Systems (NYSE: ... continuing operations of $0.64 per diluted share in the ... from continuing operations of $0.57 per diluted share in ... instruments operation, net earnings per diluted share in the ...
    ... Varian, Inc. (NasdaqGS: VARI) today reported second quarter fiscal ... 17.2% from the second quarter of fiscal year 2008.Non-GAAP ... of 2009 were $0.55 (including $0.05 of share-based compensation ... $0.07 of share-based compensation expense) in the second quarter ...
    ... juice could slow prostate cancer , , WEDNESDAY, April 29 ... a citrus flavor, might help ward off painful calcium ... citrate, which is known to inhibit calcium formation, according ... be presented Sunday at the American Urological Association annual ...
    ... years, report warns , , WEDNESDAY, April 29 (HealthDay News) -- ... of new cancers over the next two decades, driven by ... new report predicts. , Rates of new cancer diagnosis ... generally and by 67 percent among people aged 65 or ...
    ... INDIANAPOLIS , April 29 /PRNewswire/ ... a good start. WellPoint is pleased that the ... underlying quality and cost issues within our health care ... programs and services private plans have pioneered. We also ...
    ... Nancy Pelosi spoke on the House floor this morning in strong ... The resolution passed the House by a vote of 233 to ... today. It does not require the signature of the President. Below ... indeed an honor to call Mr. Spratt a colleague. We say ...
    Cached Medicine News:Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 2Health News:Varian, Inc. Reports Second Quarter 2009 Results 3Health News:Varian, Inc. Reports Second Quarter 2009 Results 4Health News:Varian, Inc. Reports Second Quarter 2009 Results 5Health News:Varian, Inc. Reports Second Quarter 2009 Results 6Health News:Varian, Inc. Reports Second Quarter 2009 Results 7Health News:Varian, Inc. Reports Second Quarter 2009 Results 8Health News:Varian, Inc. Reports Second Quarter 2009 Results 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 10Health News:Varian, Inc. Reports Second Quarter 2009 Results 11Health News:Varian, Inc. Reports Second Quarter 2009 Results 12Health News:Varian, Inc. Reports Second Quarter 2009 Results 13Health News:Varian, Inc. Reports Second Quarter 2009 Results 14Health News:Varian, Inc. Reports Second Quarter 2009 Results 15Health News:Varian, Inc. Reports Second Quarter 2009 Results 16Health News:Varian, Inc. Reports Second Quarter 2009 Results 17Health News:Varian, Inc. Reports Second Quarter 2009 Results 18Health News:Varian, Inc. Reports Second Quarter 2009 Results 19Health News:Varian, Inc. Reports Second Quarter 2009 Results 20Health News:Varian, Inc. Reports Second Quarter 2009 Results 21Health News:Varian, Inc. Reports Second Quarter 2009 Results 22Health News:Varian, Inc. Reports Second Quarter 2009 Results 23Health News:Some Diet Sodas May Ward Off Kidney Stones 2Health News:Some Diet Sodas May Ward Off Kidney Stones 3Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 2Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 3Health News:Pelosi: Budget is a Blueprint for the Future 2
    Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
    ... Cordis biopsy forceps are designed for endomyocardial biopsies. ... consist of a 3-pull ring handle, stainless steel ... thumb ring rotates to accommodate any position. ,A ... closed. The jaws are opened by moving the ...
    4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
    ... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
    Medicine Products: